Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluciclovine and PSMA PET/CT in Lobular Breast Cancer
NCT04750473Phase 1Completed
- Sponsor
- Emory University
- Start
- Jul 2021
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Emory University. Primary endpoints: Verified Detection Rate for Metastasis up to 105 days and Verified Detection Rate for Invasive Lobular Breast Cancer up to 105 days. Started Jul 2021; status: completed.
Beyond the preview
Go deeper on NCT04750473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04750473.